Recent Progress on C-4-Modified Podophyllotoxin Analogs as Potent Antitumor Agents

Medicinal Research Reviews

Volumn 35, Issue 1, 2015, Pages 1-62

  Liu, Ying Qian ^a   Tian, Jing ^a   Qian, Keduo ^b   Zhao, Xiao Bo ^a   Morris Natschke, Susan L ^b   Yang, Liu ^c   Nan, Xiang ^a   Tian, Xuan ^d   Lee, Kuo Hsiung ^b,e  

^a LANZHOU UNIVERSITY   (China)

^b University of North Carolina   (United States)

^c LANZHOU JIAOTONG UNIVERSITY   (China)

^d LANZHOU UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

C 4 position; Cytotoxic agents; Podophyllotoxin; Reviews

Indexed keywords

ANTINEOPLASTIC AGENT; C 4 MODIFIED PODOPHYLLOTOXIN DERIVATIVE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOFOS; ETOPOSIDE DERIVATIVE; O DEMETHYLASE; OXYGEN; PODOPHYLLOTOXIN DERIVATIVE; PRODRUG; SELENIUM; SULFUR; TENIPOSIDE; THIOGLUCOSE; UNCLASSIFIED DRUG; PODOPHYLLOTOXIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE ARREST; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HEMISYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; METABOLIC ACTIVATION; MICROTUBULE ASSEMBLY; SPIN LABELING; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PODOPHYLLOTOXIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84915767752     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21319     Document Type: Article

References (194)

1. Ayres DC, Loike JD. Lignans, chemical, biological and clinical properties. Cambridge: Cambridge University Press; 1990. Chapters 3 and 4.
2. Jardine I. Podophyllotoxin, in anticancer agents based on natural products models. New York: Academic Press, Inc.; 1980. p 319-351.
3. King J. Discovery of podophyllin. Coll J M Sci 1857;2:557-559.
4. Podwyssotzki V. The active constituent of podophyllin. Pharm J Trans 1881;12:217-218.
5. Podwyssotzki V. On the active constituents of podophyllin. Am J Pharm 1882;12:102-115.
6. Hartwell JL, Schrecker AW. Chemistry of podophyllum. Fortshr Chem Org Naturst 1958;15:83-166.
7. Kelly MG, Hartwell JL. The biological effects and the chemical composition of podophyllin: A review. J Natl Cancer Inst 1954;14:967-1010.
8. MacRae DW, Towers GH. Biological activity of lignans. Phytochemistry 1984;23:1207-1220.
9. Kaplan IW. Condylomata acuminata. N Orleans Med Surg J 1942;94:388-390.
10. King ML, Sullivan MM. The similarity of the effect of podophyllin and colchicine and their use in the treatment of Condylomata acuminata. Science 1946;104:244-245.
11. Sullivan BJ, Wechsler HJ. The cytological effects of podophyllin. Science 1947;105:433.
12. Stähelin H, von Wartburg A. From podophyllotoxin glucoside to etoposide. Prog Drug Res 1989;33:169-266.
13. Canetta R, Hilgard P, Florentine S, Bedogni P, Lenaz L. Current development of podophyllotoxins. Cancer Chemother Pharmacol 1982;7:93-98.
14. Kuhn M, von Wartburg A. Concerning a new glycoside preparation method. Synthesis of epipodophyllotoxin-β-D-glucopyranoside. Helv Chim Acta 1968;51:1631-1641.
15. Kuhn M, von Wartburg A. On a new glycoside synthesis process. Glycosides of 4'-demethylepipodophyllotoxin. Helv Chim Acta 1969;52:948-955.
16. Keller-Juslén C, Kuhn M, Stähelin H, von Wartburg A. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J Med Chem 1971;14:936-940.
17. Joel S. The clinical pharmacology of etoposide: An update. Cancer Treatment Rev 1996;22:179-221.
18. Stähelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 1991;51:5-15.
19. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984;44:5857-5860.
20. Long BH, Brattain MG. The activity of etoposide and teniposide against human lung tumor in vitro: Cytotoxicity and DNA breakage. In: Issell BF, Muggia FM, Carter SA, Eds. Etoposide: Current Status and New Developments. New York: Academic Press; 1984. p 223.
21. Budman DR. Early studies of etoposide phosphate, a water-soluble prodrug. Semin Oncol 1996;23:8-14.
22. Greco FA, Hainsworth JD. Clinical studies with etoposide phosphate. Semin Oncol 1996;23:45-50.
23. Long BH, Minocha A. Inhibition of topoisomerase II by VP-16 (etoposide), VM-26 (teniposide) and structure congeners as explanation for in vivo DNA breakage and cytotoxicity. Proc Am Assoc Cancer Res 1983;24:1271-1277.
24. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-1521.
25. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: A quantitative structure-activity relationship. Biochemistry 1984;23:1183-1188.
26. Saito H, Yoshikawa H, Nishimura Y, Kondo S, Takeuchi T, Umezawa H. Studies on lignan lactone antitumor agents. II. Synthesis of N-alkylamino- and 2, 6-dideoxy-2-aminoglycosidic lignan variants related to podophyllotoxin. Chem Pharm Bull 1986;34:3741-3746.
27. Pagani O, Zucchetti M, Sessa C, de Jong J, D'Incalci M, De Fusco M, Kaeser-Fröhlich A, Hanauske A, Cavalli F. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol 1996;38:541-547.
28. Lee KH. Novel antitumor agents from higher plants. Med Res Rev 1999;19:569-596.
29. Lee KH, Beers SA, Mori M, Wang ZQ, Kuo YH, Li L, Liu SY, Chang JY, Han FS, Cheng YC. Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Med Chem 1990;33:1364-1368.
30. Wang ZQ, Kuo YH, Schnur D, Bowen JP, Liu SY, Han FS, Chang JY, Cheng YC, Lee KH. Antitumor agents. 113. New 4β-arylamino derivatives of 4'-O-demethyl epipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II. J Med Chem 1990;33:2660-2666.
31. Terada T, Fujimoto K, Nomura M, Yamashita J, Wierzba K, Yamazaki R, Shibata J, Sugimoto Y, Yamada Y, Kobunai T. Antitumor agents. 3. Synthesis and biological activity of 4β-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents. J Med Chem 1993;36:1689-1699.
32. Cragg GM, Newman DJ. A Tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004;67:232-244.
33. Barret JM, Etiévant C, Baudouin C, Skov K, Charvéron M, Hill BT. F11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Res 2002;22:187-192.
34. Cho SJ, Tropsha A, Suffness M, Cheng YC, Lee KH. Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethyl-epipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach. J Med Chem 1996;39:1383-1395.
35. Imbert TF. Discovery of podophyllotoxins. Biochimie 1998;80:207-222.
36. Bohlin L, Rosen B. Podophyllotoxin derivatives: Drug discovery and development. Drug Discov Today 1996;1:343-351.
37. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-1521.
38. Ward RS. Synthesis of podophyllotoxin and related compounds. Synthesis 1992;1:719-730.
39. Damayanthi Y, Lown JW. Podophyllotoxins: Current status and recent developments. Curr Med Chem 1998;5:205-252.
40. Gordaliza M, Castro MA, del Corral JM, Feliciano AS. Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des 2000;6:1811-1839.
41. Sackett DL. Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmacol Ther 1993;59:163-228.
42. Gordaliza M, García PA, del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin: Distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004;44:441-459.
43. Desbène S, Giorgi-Renault S. Drugs that inhibit tubulin polymerization: The particular case of podophyllotoxin and analogues. Curr Med Chem Anticancer Agents 2002;2:71-90.
44. You Y. Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. Curr Pharm Des 2005;11:1695-1717.
45. Xu H, Lv M, Tian X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr Med Chem 2009;16:327-349.
46. Liu YQ, Yang L, Tian X. Podophyllotoxin: Current perspectives. Curr Bioact Compd 2007;3:37-66.
47. Lee KH. Current developments in the discovery and design of new drug candidates from plant natural product leads. J Nat Prod 2004;67:273-283.
48. Lee KH, Xiao Z. Antitumor agents 277. Podophyllotoxins and analogs. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents from Natural Products. New York: Taylor & Francis; 2011. p 95-122.
49. Lv M, Xu H. Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: An update (2008-2010). Mini Rev Med Chem 2011;11:901-909.
50. Liu CJ, Hou SS. Current research status of podophyllotoxin lignans. Nat Prod Res Dev 1997;9:81-89.
51. Pujol MD, Romero M, Sánchez I. Synthesis and biological activity of new class of dioxygenated anticancer agents. Anticancer Agents Med Chem 2005;5:215-237.
52. Bedows E, Hatfield GM. An investigation of the antiviral activity of Podophyllum peltatum. J Nat Prod 1982;45:725-729.
53. Markkanen T, Makinen ML, Maunuksela E, Himanen P. Podophyllotoxin lignans under experimental antiviral research. Drug Exp Clin Res 1981;7:711-718.
54. Gordaliza M, Castro MA, Garcia-Gracalos MD, Ruiz P, Miguel del Corral JM, Feliciano AS. Antineoplastic and antiviral activities of podophyllotoxin. Arch Pharm (Weinheim) 1994;327:175-179.
55. Hammonds TR, Denyer SP, Jackson DE, Irving WL. Studies to show that with podophyllotoxin the early replicative stages of herpes simplex virus type 1 depend upon functional cytoplasmic microtubules. J Med Microbiol 1996;45:167-172.
56. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000;54:115-120.
57. Charlton JL. Antiviral activity of lignans. J Nat Prod 1998;61:1447-1451.
58. Hara H, Fujihashi T, Sakata T, Kaji A, Kaji H. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. AIDS Res Hum Retroviruses 1997;13:695-705.
59. Markos AR. The successful treatment of Molluscum contagiosum with podophyllotoxin (0.5%) self-application. Int J STD AIDS 2001;12:833-834.
60. Mukherjee AK, Basu S, Sarkar N, Ghosh AC. Advances in cancer therapy with plant based natural products. Curr Med Chem 2001;8:1467-1486.
61. Hermanns-Lê T, Arrese JE, Goffin V, Piérard GE. Podophyllotoxin-induced acantholysis and cytolysis in a skin equivalent model. Eur J Morphol 1998;36:183-187.
62. Liu YQ, Xiao H, Gao R, Tian X. Synthesis and insecticidal activities of novel derivatives of podophyllotoxin: Part XII. Pest Biochem Physiol 2008;91:116-121.
63. Liu YQ, Zhao CY, Yang L, Zhao YL, Liu TT. Evaluation of insecticidal activity of podophyllotoxin derivatives against Brontispa longissima. Pest Biochem Physiol 2011;99:39-44.
64. Liu YQ, Zhao YL, Yang L, Zhou XW, Feng G. Design, semisynthesis and insecticidal activity of novel podophyllotoxin derivatives against Brontispa longissima in vivo. Pest Biochem Physiol 2012;102:11-18.
65. Oliva A, Moraes RM, Watson SB, Duke SO, Dayan FE. Aryltetralin lignans inhibit plant growth by affecting the formation of mitotic microtubular organizing centers. Pest Biochem Physiol 2002;72:45-54.
66. Garcia ES, Azambuja P. Lignoids in insects: Chemical probes for the study of ecdysis, excretion and Trypanosoma cruzi-triatomine interactions. Toxicon 2004;44:431-440.
67. Botta B, Delle Monache G, Misiti D, Vitali A, Zappia G. Aryltetralin lignans: Chemistry, pharmacology and biotransformations. Curr Med Chem 2001;8:1363-1381.
68. AIDS International. CPH 82. BioDrugs 2003;17:373-374.
69. Pugh N, Khan IA, Moraes RM, Pasco DS. Podophyllotoxin lignans enhance IL-1β but suppress TNF-α mRNA expression in LPS-treated monocytes. Immunopharmacol Immunotoxicol 2001;23:83-95.
70. Gordaliza M, Faircloth GT, Castro MA, Miguel del Corral JM, López-Vázquez ML, San Feliciano A. Immunosuppressive cyclolignans. J Med Chem 1996;39:2865-2868.
71. Gordaliza M, Castro MA, del Corral JMM, López-Vázquez ML, San Feliciano A, Faircloth GT. In vivo immunosuppressive activity of some cyclolignans. Bioorg Med Chem Lett 1997;21:2781-2786.
72. Loike JD, Horwitz SB. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 1976;15:5435-5443.
73. Gordaliza M, del Corral JM, Castro MA, López-Vázquez ML, San Feliciano A, García-Grávalos MD, Carpy A. Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents. Bioorg Med Chem 1995;3:1203-1210.
74. Schönbrunn E, Phlippen W, Trinczek B, Sack S, Eschenburg S, Mandelkow EM, Mandelkow E. Crystallization of a macromolecular ring assembly of tubulin liganded with the anti-mitotic drug podophyllotoxin. J Struct Biol 1999;128:211-215.
75. Cowan CR, Cande WZ. Meiotic telomere clustering is inhibited by colchicine but does not require cytoplasmic microtubules. J Cell Sci 2002;115:3747-3756.
76. Tseng CJ, Wang YJ, Liang YC, Jeng JH, Lee WS, Lin JK, Chen CH, Liu IC, Ho YS. Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicol 2002;175:123-142.
77. López-Pérez JL, del Olmo E, de Pascual Teresa B, Merino M, Barajas M, San Feliciano A. A role for dipole moment in the activity of cyclolignans. J Mol Struct (Theochem) 2000;504:51-57.
78. van Maanen JM, Retèl J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: A review. J Natl Cancer Inst 1988;80:1526-1533.
79. Champoux JJ. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
80. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drug targeted to the enzyme. Biochim Biophys Acta 1998:1400:139-154.
81. Berger JM, Gambin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996;379:225-232.
82. Haim N, Nemec J, Roman J, Sinha BK. Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26). Biochem Biophys Res Commun 1986;135:215-220.
83. Haim N, Nemec J, Roman J, Sinha BK. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 1987;47:5835-5840.
84. Sinha BK. Free radicals in anticancer drug pharmacology. Chem Biol Interact 1989;69:293-317.
85. Lin S, Huang HC, Chen LL, Lee CC, Huang TS. GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription. Mol Pharmacol 2001;60:768-775.
86. Tseng CJ, Wang YJ, Liang YC, Jeng JH, Lee WS, Lin JK, Chen CH, Liu IC, Ho YS. Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicology 2002;175:123-142.
87. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002;23:1831-1838.
88. Qi SN, Yoshida A, Wang ZR, Ueda T. GP7 can induce apoptotic DNA fragmentation of human leukemia cells through caspase-3-dependent and -independent pathways. Int J Mol Med 2004;13:163-167.
89. Qi SN, Jing YX, Dong GX, Chen Y, Yoshida A, Ueda T. GP7 induces internucleosomal DNA fragmentation independent of caspase activation and DNA fragmentation factor in NB4 cells. Oncol Rep 2007;18:273-277.
90. Suh SJ, Kim JR, Jin UH, Choi HS, Chang YC, Lee YC, Kim SH, Lee IS, Moon TC, Chang HW, Kim CH. Deoxypodophyllotoxin, flavolignan, from Anthriscus sylvestris Hoffm inhibits migration and MMP-9 via MAPK pathways in TNF-α-induced HASMC. Vasc Pharmacol 2009;51:13-20.
91. Yong Y, Shin SY, Lee YH, Lim Y. Antitumor activity of deoxypodophyllotoxin isolated from Anthriscus sylvestris: Induction of G2/M cell cycle arrest and caspase-dependent apoptosis. Bioorg Med Chem Lett 2009;19:4367-4371.
92. Shin SY, Yong Y, Kim CG, Lee YH, Lim Y. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in HeLa cells. Cancer Lett 2010;287:231-239.
93. Chen YQ, Xie X. Podophyllotoxin induces CREB phosphorylation and CRE-driven gene expression via PKA but not MAPKs. Mol Cells 2010;29:41-50.
94. Tadafumi T, Katsuhiko F, Makoto N. Antitumor agents II: Regio- and stereospecific synthesis of 1β-alkyl-1-desoxypodophyllotoxin derivatives and biological activity. Chem Pharm Bull 1993;41:907-912.
95. Tadafumi T, Katsuhiko F, Makoto . TOP-53. Drugs Future 1996;21:1136-1139.
96. Roulland E, Magiatis P, Arimondo P, Bertounesque E, Monneret C. Hemi-synthesis and biological activity of new analogues of podophyllotoxin. Bioorg Med Chem 2002;10:3463-3471.
97. Chen ZX, Ma WY, Zhang CN. Stereoselective synthesis and antitumor activities of new podophyllotoxin derivatives: 4β-Cyano-4-deoxy-4'-demethylepipodophyllotoxin and 4β-carboxyl-4-deoxy-4'-demethylepipodophyllotoxin. Chin Chem Lett 2000;11:505-508.
98. Chen ZX, Ma WY, Zhang CN. Synthesis and antitumor activity of 4-β-alkylthiocarbonyl -4-deoxy-4'-demethylepipodophyllotoxin. Chin J Med Chem 2000;10:84-87.
99. Chen ZX, Ma WY, Chen XH, Wang JD, Zhang CN. Synthesis and antitumor activity of 4-β-substituted carbamoyl-4-deoxy-4'-demethylepipodophyllotoxin. Chin J Pharm 2000;30:265-267.
100. Abad A, López-Pérez JL, del Olmo E, Garcia-Fernández LF, Francesch A, Trigili C, Barasoain I, Andreu JM, Diaz JF, San Feliciano A. Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins. J Med Chem 2012;55:6724-67377.
101. Showalterk HD, Winters RT, Sercel AD, Michel A. Facile synthesis of thioglucose analogues of the anticancer agent etoposide. Tetrahedron Lett 1991;32:2849-2852
102. Wang ZG, Ma WY, Zhang CN. Stereocontrolled synthesis of 4-sulfanyl-4-deoxy-4-demethylepipodophyllotoxin. Acta Chim Sin 1992;50:696-701.
103. Wang ZG, Yin SF, Zhuang W, Li BS, Ma WY, Zhang CN. Synthesis and antitumor activities of 4β-alkylthio-4-deoxy-4'-demethylepipodophyllotoxin and its derivatives. Acta Pharm Sin 1992;50:696-701.
104. Wang ZG, Yin SF, Zhuang W, Li BS, Ma WY, Zhang CN. Synthesis and antitumor activities of 4β-(2-aminoethylthio)-4-deoxy-4'-demethylepipodophyllotoxin and its derivatives. Chin J Pharm 1992;23:159-167.
105. Lu KK, Liu FM, Chen YZ. Synthesis and antitumor activity of podophyllotoxin analogues. J Chin Pharm Sci 1998;7:182-185.
106. Sanmartin C, Plano D, Sharma AK, Palop JA. Selenium compounds, apoptosis and other types of cell death: An overview for cancer chemotherapy. Int J Mol Sci 2012;13, 9649-9672.
107. Wang ZG, Ma WY, Zhang CN. Synthesis and antitumor activities of 4-alkylselenyl-4-deoxy-4'-demethylepipodophyllotoxin. Acta Chim Sin 1993;51:933-936.
108. Miao RD, Han Y, An LZ, Yang JB, Wang Q. Seleno-podophyllotoxin derivatives induce hepatoma SMMC-7721 cell apoptosis through Bax pathway. Cell Biol Int 2008;32:217-223.
109. Zhang YZ, Cao CN. Cytotoxicity determination and synthesis of selenoyl-4-deoxy-4'-demethylepipodophyllotoxin. J Qinghai Norm Univ 2004;3:76-79.
110. Terada T, Fujimoto K, Nomura M, Yamashita J, Kobunai T, Takeda S, Wierzba K, Yamada Y, Yamaguchi H. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Chem Pharm Bull 1992;40:2720-2727.
111. Zhuang W, Ma WY, Zhang CN. Synthesis and anticancer activity of 4β-ether-4'-demethylepipodophyllotoxin derivatives. Chin J Pharm 1991;22:446-448.
112. Yin SF, Ma WY, Zhang CN. Synthesis and antitumor activity of 4, 4'-O-bis(2-hydroxy-3-substituted-amino)propyl-4'-demethylepipodophyllotoxins. Chin J Pharm 1993;24:486-488.
113. Bathini Y, Scholte A, Kelly S, Micetich RG, Daneshtalab M. New podophyllotoxin derivatives as potential anticancer agents: Synthesis and cytotoxicity of 4β-O-propenylpodophyllotoxin ethers. Syn Commun 1999;29:379-385.
114. Levy RK, Hall IH, Lee KH. Antitumor Agents LXII: Synthesis and biological evaluation of podophyllotoxin esters and related derivatives. J Pharm Sci 1983;72:1158-1161.
115. Gupta RS, Chenchaiah PC. Synthesis and biological activities of the C-4 esters of 4'-demethylepipodophyllotoxin. Anticancer Drug Des 1987;2:13-23.
116. López-Pérez JL, del Olmo E, de Pascual-Teresa B, Abad A, San Feliciano A. Synthesis and cytotoxicity of hydrophobic esters of podophyllotoxins. Bioorg Med Chem Lett 2004;14:1283-1286.
117. Duca M, Guianvarch D, Meresse P, Bertounesque E, Dauzonne D, Kraus-Berthier L, Thirot S, Léonce S, Pierré A, Pfeiffer B, Renard P, Arimondo PB, Monneret C. Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives. J Med Chem 2005;48:593-603.
118. Kamal A, Kumar BA, Suresh P, Juvekar A, Zingde S. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents. Bioorg Med Chem 2011;19:2975-2979.
119. Mustafa J, Khan SI, Ma G, Walker LA, Khan IA. Synthesis and anticancer activities of fatty acid analogs of podophyllotoxin. Lipids 2004;39:167-172.
120. Mustafa J, Khan SI, Ma G, Walker LA, Khan IA. Synthesis and in vitro cytotoxic activity of N-, F-, and S-ether derivatives of podophyllotoxin fatty acid adducts. Lipids 2005;40:375-381.
121. Liu YQ, Wei DF, Zhao YL, Cheng WD, Lu Y, Ma YQ, Li X, Han C, Wei YX, Cao HM, Zhao CY. Synthesis and biological evaluation of a series of podophyllotoxin derivatives as a class of potent antitubulin agents. Bioorg Med Chem 2012;20:6285-6295.
122. Yu PF, Chen H, Wang J, He CX, Cao B, Li M, Yang N, Lei ZY, Cheng MS. Design, synthesis and cytotoxicity of novel podophyllotoxin derivatives. Chem Pharm Bull 2008;56:831-834.
123. Chen H, Wang J, Zhang J, Wang Y, Cao B, Bai S, Yu PF, Bi W, Xie W. L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line. Biol Pharm Bull 2009;32:609-613.
124. Gupta R, Al-said NH, Oreski B, Lown JW. Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates. Anticancer Drug Des 1996;11:325-328.
125. Derry WB, Pamidi CC, Gupta RS. Synthesis and biological activity of novel thymidine derivatives of podophyllotoxin and 4'-demethylepipodophyllotoxin. Anticancer Drug Des 1993;8:203-221.
126. Lee NJ, Jeong IC, Cho MY, Jeon CW, Yun BC, Kim YO, Kim SH, Chung I. Synthesis and in vitro antitumor activity of phthalimide polymers containing podophyllotoxin. Eur Polym J 2006;42:3352-3359.
127. Passarella D, Giardini A, Peretto B, Fontana G, Sacchetti A, Silvani A, Ronchi C, Cappelletti G, Cartelli D, Borlake J, Danieli B. Inhibitors of tubulin polymerization: Synthesis and biological evaluation of hybrids of vindoline, anhydrovinblastine and vinorelbine with thiocolchicine, podophyllotoxin and baccatin III. Bioorg Med Chem 2008;16:6269-6285.
128. Passarella D, Peretto B, Yepes RB, Cappelletti G, Cartelli D, Ronchi C, Snaith J, Fontana G, Danieli B, Borlak J. Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates. Eur J Med Chem 2010;45:219-226.
129. Cappelletti G, Cartelli D, Peretto B, Ventura M, Riccioli M, Colombo F, Snaith JS, Borrelli S, Passarella D. Tubulin-guided dynamic combinatorial library of thiocolchicine-podophyllotoxin conjugates. Tetrahedron 2011;67:7354-7357.
130. Danieli B, Giardini A, Lesma G, Passarella D, Peretto B, Sacchetti A, Silvani A, Pratesi G, Zunino F. Thiocolchicine-podophyllotoxin conjugates: Dynamic libraries based on disulfide exchange reaction. J Org Chem 2006;71:2848-2853.
131. Liu YQ, Liu YQ, Tian X, Yang L. Synthesis of novel derivatives of bispodophyllotoxin as potential antineoplastic agents-part XVI. Nat Prod Res 2008;22:285-291.
132. Allevi P, Anastasia M, Ciuffreda P. The first synthesis of the N-glucosyl analogue of the antitumor agent etoposide. Tetrahedron Lett 1993;34:7313-7316.
133. Lee KH, Imakura Y, Haruna M., Beers SA, Thurston LS, Dai HJ, Chen CH, Cheng YC. Antitumor agents. 107: New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod 1989;52:606-613.
134. Zhu XK, Guan J, Tachibana Y, Bastow KF, Cho SJ, Cheng HH, Cheng YC, Gurwith M, Lee KH. Antitumor agents. 194. Synthesis and biological evaluations of 4β-mono-, -di-, and -trisubstituted aniline-4'-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. J Med Chem 1999;42:2441-2446.
135. Zhou XM, Wang ZQ, Chang JY, Chen HX, Cheng YC, Lee KH. Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Med Chem 1991;34:3346-3350.
136. Zhou XM, Wang ZQ, Chen HX, Cheng YC, Lee KH. Antitumor agents. 125. New 4β-benzoylamino derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin and 4β-benzoyl derivatives of 4'-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II. Pharm Res 1993;10:214-219.
137. Zhang YL, Guo X, Cheng YC, Lee KH. Antitumor agents. 148. Synthesis and biological evaluation of novel 4β-amino derivatives of etoposide with better pharmacological profiles. J Med Chem 1994;37:446-452.
138. Xiao Z, Bastow KF, Vance JR, Lee KH. Antitumor agents. Part 227: Studies on novel 4'-O-demethyl-epipodophyllotoxins as antitumor agents targeting topoisomerase II. Bioorg Med Chem 2004;12:3339-3344.
139. Xiao Z, Bastow KF, Vance JR, Sidwell RS, Wang HK, Chen MS, Shi Q, Lee KH. Antitumor agents. 234. Design, synthesis, and biological evaluation of novel 4β-[(4''-benzamido)-amino]-4'-O-demethyl-epipodophyllotoxin derivatives. J Med Chem 2004;47:5140-5148.
140. Bastow KF, Wang HK, Cheng YC, Lee KH. Antitumor agents-CLXXIII. Synthesis and evaluation of camptothecin-4β-amino-4'-O-demethylepipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents. Bioorg Med Chem 1997;5:1481-1488.
141. Shi Q, Wang HK, Bastow KF, Tachibana Y, Chen K, Lee FK, Lee KH. Antitumor agents. 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg Med Chem 2001;9:2999-3004.
142. Wang ZG, Yin SF, Ma WY, Li BS, Zhang CN. Synthesis and antitumor activities of 4-acylamino-4-deoxy-4'-demethylepipodophyllotoxin analogues. Acta Pharm Sin 1993;28:422-427.
143. Tian X, Yang MG, Chen YZ. Synthesis, antitumor activity and QSAR study of derivatives of 4β-halogenated arylacylamido-4-deoxy-4'-demethylepipodophyllotoxin. J Lanzhou Univ 1998;34:114-119.
144. Hansen HF, Jensen RB, Willumsen AM, Nørskov-Lauritsen N, Ebbesen P, Nielsen PE, Buchardt O. New compounds related to podophyllotoxin and congeners: Synthesis, structure elucidation and biological testing. Acta Chim Scand 1993;47:1190-1200.
145. Kamal A, Gayatri NL, Rao NV. Facile and improved synthesis of 4β-aminopodophyllotoxin congeners. Bioorg Med Chem Lett 1998;8:3097-3100.
146. He Y, Ma WY, Chen XH, Zhang CN. Synthesis and activities of 4-deoxy-4β-arylmethylenesulfonylamino-4'-demethylpodophyllotoxins. Acta Pharm Sin 2001;36:105-107.
147. Ma WY, Li Y, Zhang CN. Synthesis and activities of 4-deoxy-4β-sulfonylamino-4'-demethylepipodophyllotoxins. Chin J Pharm 1993;24:198-201.
148. Kamal A, Gayatri NL, Reddy DR, Mohan Reddy PS, Arifuddin M, Dastidar SG, Kondapi AK, Rajkumar M. Synthesis and biological evaluation of new 4β-anilino- and 4β-imido-substituted podophyllotoxin congeners. Bioorg Med Chem 2005;13:6218-6225.
149. Kamal A, Ashwini Kumar B, Arifuddin M, Dastidar SG. Synthesis of 4β-amido and 4β-sulphonamido analogues of podophyllotoxin as potent antitumor agents. Bioorg Med Chem 2003;11:5135-5142.
150. Kamal A, Kumar BA, Arifuddin M, Dastidar SG. Synthesis and biological activity of new 4β-N-heteroaryl analogues of podophyllotoxin. Lett Drug Des Dis 2006;3:205-213.
151. Kamal A, Laxman E, Khanna GB, Reddy PS, Rehana T, Arifuddin M, Neelima K, Kondapi AK, Dastidar SG. Design, synthesis, biological evaluation and QSAR studies of novel bisepipodophyllotoxins as cytotoxic agents. Bioorg Med Chem 2004;12:4197-4209.
152. Kamal A, Kumar BA, Suresh P, Agrawal SK, Chashoo G, Singh SK, Saxena AK. Synthesis of 4β-N-polyaromatic substituted podophyllotoxins: DNA topoisomerase inhibition, anticancer and apoptosis-inducing activities. Bioorg Med Chem 2010;18:8493-8500.
153. Kamal A, Kumar BA, Suresh P, Shankaraiah N, Kumar MS. An efficient one-pot synthesis of benzothiazolo-4β-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity. Bioorg Med Chem Lett 2011;21:350-353.
154. Kamal A, Suresh P, Janaki Ramaiah M, Mallareddy A, Kumar BA, Raju P, Vinay Gopal J, Pushpavalli SN, Lavanya A, Sarma P, Pai-Bhadra M. Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents. Bioorg Med Chem 2011;19:4589-4600.
155. Kamal A, Mallareddy A, Suresh P, Lakshma Nayak V, Shetti RV, Sankara Rao N, Tamboli JR, Shaik TB, Vishnuvardhan MV, Ramakrishna S. Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents. Eur J Med Chem 2012;47:530-545.
156. Kamal A, Suresh P, Ramaiah MJ, Mallareddy A, Imthiajali S, Pushpavalli SN, Lavanya A, Pai-Bhadra M. Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents. Bioorg Med Chem 2012;20:2054-2066.
157. Kamal A, Tamboli JR, Vishnuvardhan MV, Adil SF, Nayak VL, Ramakrishna S. Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents. Bioorg Med Chem Lett 2013;23:273-280.
158. Zhang FM, Tian X. Synthesis and anticancer activity of novel derivatives of 4′-demethylepipodophyllotoxin. Acta Chim Sin 2002;60:720-724.
159. Liu YQ, Yang H, Tian X. Design, synthesis and biological evaluation of novel etoposide analogue as cytotoxic agents. Chin J Chem 2006;24:785-790.
160. Chen SW, Tian X, Tu YQ. Synthesis and cytotoxic activity of novel derivatives of 4′-demethylepipodophyllotoxin. Bioorg Med Chem Lett 2004;14:5063-5066.
161. Chen SW, Xiang R, Liu J, Tian X. Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents. Bioorg Med Chem 2009;17:3111-3117.
162. Guianvarch D, Duca M, Boukarim C, Kraus-Berthier L, Léonce S, Pierré A, Pfeiffer B, Renard P, Arimondo PB, Monneret C, Dauzonne D. Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J Med Chem 2004;47:2365-2374.
163. Guo YE, Chen H, Zuo S, Liu DL, Lu YL, Lv JJ, Wen SP, Zhang TC. Synthesis and antitumor activity of novel podophyllotoxin derivatives against multidrug-resistant cancer cells. J Asian Nat Prod Res 2011;13:417-424.
164. Shang H, Chen H, Zhao DM, Tang XW, Liu YF, Pan L, Cheng MS. Synthesis and biological evaluation of 4α/4β-imidazolylpodophyllotoxin analogues as antitumor agents. Arch Pharm Chem Life Sci 2012;345:43-48.
165. Wang L, Yang FY, Yang XC, Guan XH, Hu CQ, Liu T, He QJ, Yang B, Hu YZ. Synthesis and biological evaluation of new 4β-anilino-4'-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents. Eur J Med Chem 2011;46:285-296.
166. Wang CN, Wu ZH, Zhao Y, Ni CY, Zhao XD, Zhu L. Synthesis and cytotoxicity evaluation of novel podophyllotoxin derivatives. Arch Pharm Chem Life Sci 2011;344:735-740.
167. Ren J, Wu L, Xin WQ, Chen X, Hu K. Synthesis and biological evaluation of novel 4β-(1, 3, 4-oxadiazole-2-amino)-podophyllotoxin derivatives. Bioorg Med Chem Lett 2012;22:4778-4782.
168. Zhao Y, Ge CW, Wu ZH, Wang CN, Fang JH, Zhu L. Synthesis and evaluation of aroylthiourea derivatives of 4β-amino-4'-O-demethyl-4-desoxypodophyllotoxin as novel topoisomerase II inhibitors. Eur J Med Chem 2011;46:901-906.
169. Tao L, Wang YG, Ma C, Zheng B, Chen YZ. Synthesis of 4β-(1, 2, 3-triazol-1-yl) podophyllotoxins as potential antitumor drugs. Syn Commun 1999;29:2053-2059.
170. Cao CN, Chen YY, Wang YG, Chen YZ. Synthesis and antitumor activity of 4-(1, 2, 3-triazol-1-yl) podophyllotoxins. Chin Chem Lett 1999;10:1003-1006.
171. Bhat BA, Reddy PB, Agrawal SK, Saxena AK, Kumar HM, Qazi GN. Studies on novel 4β-[(4-substituted)-1, 2, 3-triazol-1-yl] podophyllotoxins as potential anticancer agents. Eur J Med Chem 2008;43:2067-2072.
172. Reddy PB, Agrawal SK, Singh S, Bhat BA, Saxena AK, Kumar HM, Qazi GN. Synthesis and biological evaluation of 4β-[(4-substituted)-1, 2, 3-triazol-1-yl] podophyllotoxins as potential anticancer agents. Chem Biodiver 2008;5:1792-1802.
173. Reddy PB, Paul DV, Agrawal SK, Saxena AK, Kumar M, Qazi GN. Design, synthesis, and biological testing of 4β-[(4-substituted)-1, 2, 3-triazol-1-yl]podophyllotoxin analogues as antitumor agents. Arch Pharm (Weinheim) 2008;341:126-131.
174. Reddy DM, Srinivas J, Chashoo G, Saxena AK, Sampath Kumar HM. 4β-[(4-Alkyl)-1, 2, 3-triazol-1-yl]podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation. Eur J Med Chem 2011;46:1983-1991.
175. Chen H, Zuo S, Wang X, Tang X, Zhao M, Lu Y, Chen L, Liu J, Liu Y, Liu D, Zhang S, Li T. Synthesis of 4β-triazole-podophyllotoxin derivatives by azide-alkyne cycloaddition and biological evaluation as potential antitumor agents. Eur J Med Chem 2011;46:4709-4714.
176. Chen J, Ma L, Zhang R, Tang J, Lai H, Wang J, Wang G, Xu Q, Chen T, Peng F, Qiu J, Liang X, Cao D, Ran Y, Peng A, Wei Y, Chen L. Semi-synthesis and biological evaluation of 1, 2, 3-triazole-based podophyllotoxin congeners as potent antitumor agents inducing apoptosis in HepG2 cells. Arch Pharm (Weinheim) 2012;345:945-956.
177. Wang YG, Tian X, Chen YZ. Recent advances in spin labeled anticancer drugs. Acta Pharm Sin 1988;23:792-798.
178. Liu YQ, Tian X, Yang L, Zhan ZC. First synthesis of novel spin-labeled derivatives of camptothecin as potential antineoplastic agents. Eur J Med Chem 2008;43:2610-2614.
179. Liu YQ, Ohkoshi E, Li LH, Yang L, Lee KH. Design, synthesis and cytotoxic activity of novel spin-labeled rotenone derivatives. Bioorg Med Chem Lett 2012;22:920-923.
180. Liu Y, Qian K, Wang CY, Chen CH, Yang XM, Lee KH. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives. Bioorg Med Chem Lett 2012;22:7530-7533.
181. Chen YZ, Zhang CJ, Tian X. Spin-labeled antitumor derivatives of podophyllotoxin. Sci Sin B 1987;30:1070-1079.
182. Tian X, Yan ZQ, Li JX, Chen YZ. Anticancer drugs (V)-Synthesis of etoposide derivatives. Chem Res Chin Univ 1995;11:79-83.
183. Tian X, Yang MG, Chen YZ. Anticancer drugs (VI)-Synthesis and activity of spin labeled derivatives of 4-amino-4-deoxy-4'-demethylepipodophyllotoxin. Chem Res Chin Univ 1996;12:304-308.
184. Lu KK, Wang YG, Chen YZ. Synthesis of novel spin labeled analogues of podophyllotoxin glycoside. Syn Commun 1997;27:1963-1968.
185. Wang YG, Pan JL, Shi JF, Chen YZ. New spin labeled analogues of podophyllotoxin as potential antitumor agents. Life Sci 1997;61:537-542.
186. Pan JL, Wang YG, Shi JF, Chen YZ. Synthesis of new spin labeled derivatives of podophyllotoxin as potential anticancer agents. Chin Chem Lett 1997;8:207-208.
187. Tian X, Zhang FM, Li WG. Antitumor and antioxidant activity of spin labeled derivatives of podophyllotoxin (GP-1) and congeners. Life Sci 2002;70:2433-2443.
188. Wang JZ, Tian X, Tsumura H, Shimura K, Ito H. Antitumor activity of a new low immunosuppressive derivative of podophyllotoxin (GP-11) and its mechanisms. Anticancer Drug Des 1993;8:193-202.
189. Chen YZ, Wang YG, Li JX, Tian X, Jia ZP, Zhang PY. Anticancer drugs. II. Synthesis and biological evaluation of spin labeled derivatives of podophyllotoxin. Life Sci 1989;45:2569-2575.
190. Tian X, Wang YG, Yang MG, Chen YZ. Synthesis and antitumor activity of spin labeled derivatives of podophyllotoxin. Life Sci 1997;60:511-517.
191. Jin Y, Chen SW, Tian X. Synthesis and biological evaluation of new spin-labeled derivatives of podophyllotoxin. Bioorg Med Chem 2006;14:3062-3068.
192. Liu YQ, Tian X. Synthesis of novel spin-labeled derivatives of podophyllotoxin as potential antineoplastic agents. Syn Commun 2005;35:2479-2758.
193. Yang L, Liu YQ, Tan H, Li WG, Tian X. Design, synthesis, and biological evaluation of novel spin-labeled derivatives of podophyllotoxin as potential antineoplastic agents. Part XII. Nat Prod Res 2007;21:998-1008.
194. Zhang JQ, Zhang ZW, Hui L, Chen SW, Tian X. Novel semisynthetic spin-labeled derivatives of podophyllotoxin with cytotoxic and antioxidative activity. Bioorg Med Chem Lett 2010;20:983-986.